Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective
Deepam Pushpam, Sameer Bakhshi
Topics & Concepts
MedicineBosutinibNilotinibDasatinibImatinibPonatinibClinical trialOncologyPharmacologyPharmacogenomicsTyrosine-kinase inhibitorPharmacodynamicsImatinib mesylateMyeloid leukemiaAdverse effectTyrosine kinaseInternal medicineIntensive care medicinePharmacokineticsCancerReceptorChronic Myeloid Leukemia TreatmentsFibroblast Growth Factor ResearchPhagocytosis and Immune Regulation